

Materials for this course will release 03/30/2022

Oncology Pharmacy Specialty Review Course, Workbook Chapters (No Recert Credit (Cert # L229087))

Teaser: This online Specialty Review Course and Workbook package will help you prepare for the Board of Pharmacy Specialty (BPS) examination. With this course, get comprehensive, practical guidance, with a variety of complex cases, including references for further study.

Tag: Certifications; Oncology



ACPE Numbers: Various – see listing below

Pre-Sale Date: 03/16/2022

Content Release Date: 03/30/2022

Expiration Date: 02/14/2023

Activity Type: Application-based

CE Credits: 25.75 hours (ACPE only)

Activity Fee: \$425 (ASHP member); \$625 (non-member)

Accreditation for Pharmacists



The American Society of Health-System Pharmacists (ASHP) and the American College of Clinical Pharmacy (ACCP) are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

These activities were recorded during a live educational event on March 3-5, 2022, at the ACCP/ASHP's 2022 Live Review & Recertification Courses, Henderson, Nevada. Learners who claimed credit for the live activities should not claim credit for these home study activities.

Target Audience

These activities are intended for pharmacists who are seeking to update their knowledge and skills commensurate with a board certification examination in the areas listed below.

Activity Overview

This online course provides a robust preparatory curriculum for the pharmacy professional preparing for the Board of Pharmacy Specialties (BPS) Oncology Specialty Certification Examination. Designed based on the domains, tasks, and knowledge statements developed by the BPS for the certification examination, this course will help you prepare for the exam by identifying areas needed for in-depth review of oncology issues by:

- Reviewing pertinent clinical topics and practice skills
- Listing valuable references for further study

This course is **NOT** intended for those obtaining recertification credit. To earn recertification credit, please see courses here: <http://elearning.ashp.org/catalog/onc-recert>

These activities are part of the ASHP and ACCP professional development program.

Materials for this course will release 03/30/2022

REVIEW COURSE

This course consists of 20 activities (see table below) and provides up to 25.75 hours of continuing pharmacy education credit. The Review Course includes case-based presentations for application to real-life scenarios and links to the reference sources, and domains, tasks, and knowledge statements.

Learning Module	ACPE Number	Credit Hours	ACPE Expiration Date
Breast Cancer	0204-9999-22-912-H01-P	2.50	03/30/2025
Gynecologic Malignancies	0204-9999-22-913-H01-P	1.00	03/30/2025
Prostate Cancer	0204-9999-22-914-H01-P	1.00	03/30/2025
Pediatric Malignancies and Supportive Care	0204-9999-22-915-H01-P	1.25	03/30/2025
Upper Gastrointestinal and Hepatocellular Carcinomas	0204-9999-22-916-H01-P	0.75	03/30/2025
Bladder, Renal Cell, and Testicular Cancers	0204-9999-22-929-H01-P	1.00	03/30/2025
Melanoma and Non-Melanoma Skin Cancers	0204-9999-22-917-H01-P	1.00	03/30/2025
Research Design, Statistics, and Evaluating Oncology Literature	0204-9999-22-918-H04-P	2.00	03/30/2025
Adult Acute Leukemias and Myelodysplastic Syndromes	0204-9999-22-919-H01-P	1.50	03/30/2025
Lymphomas	0204-9999-22-920-H01-P	1.25	03/30/2025
Chronic Leukemias	0204-9999-22-921-H01-P	1.50	03/30/2025
Hematopoietic Stem Cell Transplantation	0204-9999-22-922-H01-P	1.25	03/30/2025
Lung Cancer	0204-9999-22-923-H01-P	1.50	03/30/2025
Lower Gastrointestinal and Pancreatic Cancers	0204-9999-22-924-H01-P	1.25	03/30/2025
Head, Neck, Adult Central Nervous System (CNS), and Thyroid Malignancies	0204-9999-22-930-H01-P	1.00	03/30/2025
Cancer-related Infectious Diseases	0204-9999-22-931-H01-P	1.00	03/30/2025
Oncology Practice Management	0204-9999-22-925-H04-P	2.00	03/30/2025
Multiple Myeloma	0204-9999-22-926-H01-P	1.50	03/30/2025
Adult Sarcomas	0204-9999-22-927-H01-P	0.75	03/30/2025
Pharmacogenomics in Oncology	0204-9999-22-928-H01-P	0.75	03/30/2025

Materials for this course will release 03/30/2022

Learning Objectives

At the end of the presentations, the pharmacist should be able to:

Breast Cancer

ACPE #: 0204-9999-22-912-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with breast cancer.
- Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with breast cancer and her or his caregiver.
- Determine appropriate pharmacotherapy for a patient with breast cancer based on genomic test results.
- Identify appropriate diagnostic and prognostic tests related to breast cancer.
- Select relevant information and guidance for the public regarding breast cancer-related issues (e.g., cancer risk factors, prevention, screening).

Gynecologic Malignancies

ACPE #: 0204-9999-22-913-H01-P

- Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes of clinical trials and current treatment guidelines for a patient with a gynecologic malignancy.
- Discuss short and long-term goals, including post-therapy and survivorship, with a patient with a gynecologic malignancy and her caregiver.
- Select relevant information and provide guidance for the public regarding gynecologic malignancy-related issues (e.g., risk factors, prevention, and screening).

Prostate Cancer

ACPE #: 0204-9999-22-914-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with prostate cancer.
- Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with prostate cancer and his caregiver.
- Select relevant information and guidance for the public regarding prostate cancer-related issues (e.g., risk factors, prevention, screening).

Pediatric Malignancies and Supportive Care

ACPE #: 0204-9999-22-915-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for pediatric patients with cancer.
- Assess the prognostic impact of relevant cancer-related molecular biology testing for a pediatric patient with cancer.
- Discuss with a pediatric patient who has cancer and his or her caregiver the short- and long-term treatment goals, including post-therapy and survivorship.
- Assess the regulatory, ethical, and patient rights issues related to conducting research, including informed consent and confidentiality.

Materials for this course will release 03/30/2022

Upper Gastrointestinal and Hepatocellular Carcinomas

ACPE #: 0204-9999-22-916-H01-P

- Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with esophageal, gastric, or hepatic malignancies.
- Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer agents used for gastrointestinal malignancies.
- Develop an appropriate plan for preventing, monitoring, and treating radiation recall and other complications of radiation therapy.

Bladder, Renal Cell, and Testicular Cancers

ACPE #: 0204-9999-22-929-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with bladder, renal, or testicular carcinomas.
- Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with bladder, renal, or testicular carcinomas and his or her caregiver.
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment with tyrosine kinase inhibitors and mTOR inhibitors.

Melanoma and Non-Melanoma Skin Cancers

ACPE #: 0204-9999-22-917-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with melanoma or non-melanoma skin cancer.
- Discuss short- and long-term goals, including post-therapy and survivorship, with a patient with melanoma or non-melanoma skin cancer and his or her caregiver.
- Select relevant information and guidance for the public regarding melanoma and non-melanoma skin cancer-related issues (e.g., risk factors, prevention, screening).
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of melanoma and non-melanoma skin cancers, including thyroid level monitoring for chemotherapy agents, immune-mediated toxicities, and toxicity from BRAF inhibitors.

Research Design, Statistics, and Evaluating Oncology Literature

ACPE #: 0204-9999-22-918-H04-P

- Evaluate the oncology literature, including study design, identification of sources of bias, methodology, statistical analysis, and applicability of results to clinical practice for the oncology patient population.
- Interpret the validity and results of various types of oncology studies (e.g., meta-analyses, noninferiority trials).
- Interpret findings from the use of study endpoints (e.g., objective response, time to progression, adverse events, quality of life, overall survival) in oncology research.
- Interpret sensitivity, specificity, positive and negative predictive values, measures of effect, correlation, and regression for an oncology study.

Materials for this course will release 03/30/2022

Adult Acute Leukemias and Myelodysplastic Syndromes

ACPE #: 0204-9999-22-919-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adults with acute leukemia or myelodysplastic syndrome.
- Assess the prognostic impact of relevant cancer-related molecular biology testing for an adult with acute leukemia or myelodysplastic syndrome.
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions from pharmacotherapy for acute leukemia and myelodysplastic syndrome in an adult, including tumor lysis syndrome, neurotoxicity, differentiation syndrome, and cardiac toxicity from arsenic trioxide, and other agents as appropriate.
- Determine appropriate pharmacotherapy for acute leukemia or myelodysplastic syndrome in an adult based on genomic test results.

Lymphomas

ACPE #: 0204-9999-22-920-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan to include effectiveness, toxicities and outcomes, based on the most current guidelines for patients with lymphoma.
- Assess the prognostic impact of relevant cancer-related molecular biology testing.
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lymphoma and other cancers, including chemotherapy-induced pulmonary toxicities and extravasation.

Chronic Leukemias

ACPE #: 0204-9999-22-921-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration relevant molecular biology testing, genomic information, efficacy and safety outcomes from clinical trials, and current treatment guidelines for patients with chronic leukemia.
- Develop an appropriate plan for preventing, monitoring, and treating infusion-related reactions from monoclonal antibodies used in the treatment of hematologic malignancies.
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for the treatment of cancers, including toxicities from tyrosine kinase inhibitors used to treat hematologic cancers.

Hematopoietic Stem Cell Transplantation

ACPE #: 0204-9999-22-922-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients undergoing hematopoietic stem cell transplantation (HSCT).
- Apply appropriate strategies to prevent and treat toxicity from chemotherapy agents employed in HSCT conditioning regimens.
- Create a plan for prevention and management of acute and chronic graft-versus-host disease (GVHD) using appropriate systemic and ancillary therapies.
- Discuss short- and long-term treatment goals, including post-therapy and survivorship, with the patient undergoing HSCT and his or her caregiver.

Materials for this course will release 03/30/2022

Lung Cancer

ACPE #: 0204-9999-22-923-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lung cancer.
- Select relevant information and guidance for the public regarding lung cancer-related issues (e.g., risk factors, prevention, screening).
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lung cancer.
- Develop a prevention and management strategy for chemotherapy-induced nausea and vomiting for patients with any type of cancer.

Lower Gastrointestinal and Pancreatic Cancers

ACPE #: 0204-9999-22-924-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lower gastrointestinal (GI) or pancreatic cancers.
- Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with lower GI or pancreatic cancers and his or her caregiver.
- Select relevant information and guidance for the public regarding lower GI and pancreatic cancer-related issues (e.g., risk factors, prevention, screening).
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lower GI or pancreatic cancers, including chemotherapy-induced diarrhea, hand-foot syndrome, hand-foot skin reaction, neurotoxicity from oxaliplatin, and dermatologic toxicities from epidermal growth factor receptor inhibitors.

Head, Neck, Adult Central Nervous System (CNS), and Thyroid Malignancies

ACPE #: 0204-9999-22-930-H01-P

- Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with head, neck, adult central nervous system (CNS), or thyroid cancers.
- Select relevant information and guidance for the public regarding head and neck cancer-related issues (e.g., risk factors, prevention, screening).
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of cancers including cancer cachexia, mucositis, and xerostomia.

Cancer-related Infectious Diseases

ACPE #: 0204-9999-22-931-H01-P

- Design an appropriate patient-specific management and monitoring plan to address potential infection-related problems that may arise during and following cancer treatment based on current guidelines for treating cancer-related infectious diseases.
- Discuss short- and long-term treatment goals, including post-therapy, with a patient with cancer-related infectious disease and his or her caregiver.

Materials for this course will release 03/30/2022

Oncology Practice Management

ACPE #: 0204-9999-22-925-H04-P

- Evaluate oncology pharmacy services for compliance with established regulations, professional practice standards, and procedures for safe handling, administration, and disposal of hazardous drugs.
- Select quality-improvement activities that enhance the safety and effectiveness of the medication-use process in oncology patient care.
- Explain national accreditation and federal regulatory requirements for the care of cancer patients receiving chemotherapy or other hazardous drugs.
- Explain medication reimbursement and patient assistance programs to optimize drug availability for oncology patients.
- Evaluate policies and procedures related to conducting research involving investigational drugs, including drug management in patients with cancer.

Multiple Myeloma

ACPE #: 0204-9999-22-926-H01-P

- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients with multiple myeloma.
- Evaluate oncology pharmacy services for compliance with established REMS regulations and standards.
- Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of cancers, including bone metastases, thromboembolism, hypercalcemia of malignancy, and spinal cord compression.

Adult Sarcomas

ACPE #: 0204-9999-22-927-H01-P

- Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adult patients with sarcoma.
- Adjust treatment and monitoring plans as needed based on the tumor genetics and pharmacokinetics of anticancer and supportive-care agents (e.g., methotrexate).
- Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of adult patients with cancer, including neurotoxicity from ifosfamide and hemorrhagic cystitis.

Pharmacogenomics in Oncology

ACPE #: 0204-9999-22-928-H01-P

- Identify appropriate considerations for genetic interpretation in both the germline and somatic settings utilizing a variety of next generation sequencing techniques.
- Apply the results from somatic and germline genetic testing into therapy recommendations based on prognostic, predictive and patient characteristics.
- Recognize the place in therapeutic decision making for companion diagnostic testing.

Materials for this course will release 03/30/2022

Faculty

Jessica Auten, Pharm.D., BCOP
Clinical Pharmacy Specialist, Acute Care Malignant Hematology
UNC Medical Center
Chapel Hill, North Carolina

John Bossaer, Pharm.D., BCPS, BCOP
Professor
Bill Gatton College of Pharmacy at ETSU
Johnson City, Tennessee

Courtney C. Cavalieri, Pharm.D., BCOP*
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah

Brette Conliffe, Pharm.D., BCOP
Clinical Oncology Pharmacist
University of Louisville Health/Brown Cancer Center
Louisville, Kentucky

Karen M. Fancher, Pharm.D., BCOP*
Associate Professor of Pharmacy Practice/ Clinical Pharmacy Specialist - Oncology
Duquesne University School of Pharmacy/UPMC Passavant Hospital
Pittsburgh, Pennsylvania

Christopher Fausel, Pharm.D., M.H.A., BCOP
Clinical Specialist – Precision Medicine
Indiana University Simon Comprehensive Cancer Center
Indianapolis, Indiana

Kelly Fritz, Pharm.D., BCOP
Oncology Clinical Coordinator
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah

Lauren Ice, Pharm.D., BCOP, BCPS
Clinical Pharmacy Specialist
Spectrum Health
Grand Rapids, Michigan

Alexis R. Jones, Pharm.D., BCOP, CPP
Clinical Pharmacist, Gynecologic Oncology
University of North Carolina Medical Center
Chapel Hill, North Carolina

Elyse A. MacDonald, Pharm.D., M.S., BCPS
Director, Pharmacy Services, Investigational Drug Service
Stanford Health Care
Palo Alto, California

Janelle Mann, Pharm.D., BCOP
Clinical Oncology Pharmacist/Manger, Clinical Pharmacy Services
Alvin J. Siteman Cancer Center/Washington University School of Medicine in St. Louis
St. Louis, Missouri

Anthony J. Perissinotti, Pharm.D., BCOP
Hematology Clinical Pharmacist Specialist
University of Michigan – Michigan Medicine
Ann Arbor, Michigan

Danielle Roman, Pharm.D., BCOP*
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania

Christine M. Walko, Pharm.D., BCOP, FCCP*
Associate Member, Individualized Cancer Management
H. Lee Moffitt Cancer Center
Tampa, Florida

Jennifer Young, Pharm.D., BCOP
Clinical Pharmacy Specialist – Pediatric Oncology
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio

**Content Matter Experts*

Materials for this course will release 03/30/2022

Reviewers

Marin Abousaud, Pharm.D., BCOP	Jeff Kaiser, Pharm.D., BCOP, BCPS
Jonathan Angus, Pharm.D., BCOP	Shraddha Kansagra, Pharm.D., BCOP
Allison Bass, Pharm.D., BCOP	Jessica LeClair, Pharm.D., M.B.A., BCOP
Colleen Bohnenkamp, Pharm.D., BCOP, BCPS	Matthew Lei, Pharm.D., BCOP
Janet Bramell, Pharm.D., BCPS, BCOP	Whitney Lewis, Pharm.D., BCOP
Theresa Brown, Pharm.D., BCOP, CPP	Claire Mach, Pharm.D., BCOP
Ryan Bycroft, Pharm.D., BCOP	Jennifer Martin, Pharm.D., BCOP
Peter Campbell, Pharm.D., BCOP	Colleen McCabe, Pharm.D., BCOP
Ansley Chambers, Pharm.D., BCOP	Donald Moore Pharm.D., BCPS, BCOP, DPLA
Soniya Chandrasekhara, Pharm.D.	Matthew Newman, Pharm.D., MEHP, BCOP
Kevin Chen, Pharm.D., M.S., BCOP, CPP	Nancy Nix, Pharm.D., BCPS, BCOP
Jill Comeau, Pharm.D., BCOP	Carolyn Oxencis, Pharm.D., BCOP
Wendy Covert, Pharm.D., BCOP	Makenna Smack, Pharm.D., BCOP
Laura Darland, Pharm.D., BCOP	Anne Spengler, Pharm.D., BCOP, APh
Sara deHoll, PharmD, BCOP	Kelsey Turcotte, Pharm.D., BCOP
Kathy Edwards, B.S., Pharm.D., BCPS, BCOP, FHOPA	Courtney Watts Alexander, Pharm.D., BCPS, BCOP
Bryna Ewachiw, Pharm.D., BCOP	Taylor Weis, Pharm.D., BCOP
Ashley Glode, Pharm.D., BCOP	Lourdes Wong, Pharm.D., BCOP, BCSCP
Mitchell Hughes, Pharm.D., BCPS, BCOP	Lily Yan, Pharm.D., BCOP
Jennifer Hutchinson, Pharm.D., BCOP	Spencer Yingling, Pharm.D., BCOP

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support and the Accreditation Council for Pharmacy Education's Standards for Commercial Support, ASHP and ACCP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and ACCP and required to disclose any relevant financial relationships with commercial interests. ASHP and ACCP identifies and resolves conflicts of interest prior to an individual's participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

- Karen Fancher is Consultant, AstraZeneca, LP; Consultant, Merck & Co.; Consultant, speakers bureau, BTG Specialty Pharmaceuticals
- Alexis R. Jones is Multidisciplinary Council Member, Eisai; Content developer, KellyCPharmD
- Anthony J. Perissinotti is Consultant, Amgen; consultant, Pfizer; consultant, Servier
- Christine M. Walko is Consultant, Foundation Medicine; MTB Consultant, Jackson Genetic Laboratories; MTB Consultant, Intermountain Healthcare

All other planners, presenters, reviewers, ASHP and ACCP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Materials for this course will release 03/30/2022

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the [minimum technical and system requirements](#) for learning activities.

Development

These activities were developed by ASHP and ACCP.

To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations.